atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 Post published:January 12, 2023 Post category:Press Release
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression Post published:January 6, 2023 Post category:Press Release
atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial Post published:January 6, 2023 Post category:Analysis
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital Post published:December 16, 2022 Post category:Press Release
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer Post published:November 29, 2022 Post category:Press Release
Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout Post published:November 17, 2022 Post category:Analysis
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment Post published:November 17, 2022 Post category:Press Release
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update Post published:November 10, 2022 Post category:Press Release
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences Post published:November 2, 2022 Post category:Press Release
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression Post published:October 25, 2022 Post category:Press Release